Home

Our Approach

Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Learn More ButtonLearn More Button

Pipeline

The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.

View Pipeline ButtonPipeline View Button

Clinical Trials

We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Find Out More ButtonFind Out More Button

News

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
Mr. Squarer, a global biopharmaceutical leader, brings extensive oncology commercialization expertise as Company prepares to submit BLA in Q3 2020 Lausanne, Switzerland, March 19, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors,

ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs

ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
Former Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission   Lausanne, Switzerland, January 10, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Exceeded primary endpoint target with 45.5% overall response rate, including 20% complete response rate, in 145-patient trial On track for Biologics License Application (BLA) submission in 3Q 2020   Lausanne, Switzerland, January 9, 2020 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs)